CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


CA Cancer J Clin 2006; 56:354-365
doi: 10.3322/canjclin.56.6.354
© 2006 American Cancer Society
This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrow Freely available CME: Take the course for this article:
Preventing Occupational Exposures to Antineoplastic Drugs in Health Care Se...
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Connor, T. H.
Right arrow Articles by McDiarmid, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Connor, T. H.
Right arrow Articles by McDiarmid, M. A.

Preventing Occupational Exposures to Antineoplastic Drugs in Health Care Settings

Thomas H. Connor, PhD and Melissa A. McDiarmid, MD, MPH

Dr. Connor is Research Biologist, Division of Applied Research and Technology, The National Institute for Occupational Safety and Health, Cincinnati, OH.
Dr. McDiarmid is Professor of Medicine, University of Maryland School of Medicine, Baltimore, MD.

This article is available online at http://CAonline.AmCancerSoc.org

The toxicity of antineoplastic drugs has been well known since they were introduced in the 1940s. Because most antineoplastic drugs are nonselective in their mechanism of action, they affect noncancerous as well as cancerous cells, resulting in well-documented side effects. During the 1970s, evidence came to light indicating health care workers may be at risk of harmful effects from antineoplastic drugs as a result of occupational exposure. Since that time, reports from several countries have documented drug contamination of the workplace, identified drugs in the urine of health care workers, and measured genotoxic responses in workers. Evidence also exists of teratogenic and adverse reproductive outcomes and increased cancers in health care workers. During the past 30 years, professional organizations and government agencies have developed guidelines to protect health care workers from adverse effects from occupational exposure to antineoplastic drugs. Although many safety provisions were advanced to reduce worker exposure in the 1980s, recent studies have shown that workers continue to be exposed to these drugs despite safety policy improvements. In 2004, the National Institute for Occupational Safety and Health (NIOSH) published an alert reviewing the most recent information available and promoting a program of safe handling during their use.




This article has been cited by other articles:


Home page
ANN OCCUP HYGHome page
J. Yoshida, G. Tei, C. Mochizuki, Y. Masu, S. Koda, and S. Kumagai
Use of a Closed System Device to Reduce Occupational Contamination and Exposure to Antineoplastic Drugs in the Hospital Work Environment
Ann. Hyg., March 1, 2009; 53(2): 153 - 160.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by American Cancer Society.